Attempts to improve prevention and develop cures are highly appreciated. Indeed, many approaches and models to prevent and cure diseases have been developed and pursued. However, a major challenge in research is to improve the effectiveness of existing drugs. For this purpose, many avenues and approaches have been explored, but fighting a viral infection remains a challenge, mainly because of the resistance of the virus to existing drugs or vaccines. The establishment of a compatible system and offering a reproducible response are favourable to achieve a well-organised and regulated health system. Permissible medicine "Halalopathy" has been introduced as a new model for building a compatible system between mind, and health system. Halalopathy provides a new approach to preventing disease by managing the entropic state and/or facilitating recovery by implementing the concept of permissible medicine. Halalopathy activates potential by creating a compatible relationship between therapeutic medicines and behaviours that can affect epigenetic traits such as lifestyle. The compatibility sets up a highly ordered system that has reduced entropy and enriched potential energy. Entropy was introduced by halalopathy as an essential element in the prevention and cure of disease. Potential energy dispersion and entropy enrichment can be used to prevent and/or cure COVID-19. The method is based on Le Chatelier's principle and utilises safe and available substances that can be easily taken by most patients. There is potential for the proposed method to reduce COVID-19 to a threshold level that might boost the patient's immune system and enhance recovery.
Dr. Jawad Alzeer was born in Hebron, Palestine, graduated from Alhusein high school, and attended college at Karachi University, Pakistan, earning a B.Sc. in Chemistry, M.Sc. in Organic Chemistry, secured second position with distinction. In 1996, he received his PhD in Organic Chemistry from the Swiss Federal Institute of Technology (ETH) Zurich where he developed a cellulose analogue by replacing the glycosidic linkage with butadiyne units. After PhD, Alzeer joined Hoffmann La Roche as a postdoc and developed a new pharmacophore for antimalarial drug, then moved to Michigan University where he got involved in the discovery of new RT HIV inhibitor, following that he joined University of Zurich to become a Research Associate, during his stay at Zurich University he was involved in the design of chemical approach for targeted mutagenesis and evaluation of potential anticancer compounds that inhibit telomerase enzyme. From 2009 to 2010, Alzeer worked as a senior scientist at Swiss health care company, Lipomed. In 2010, Alzeer joined Halal Certification Service as a senior consultant, highly specialized in auditing pharmaceutical and other chemical companies. Meanwhile Alzeer was appointed as an assistant Professor at Palestine Polytechnic University (PPU) during his stay at PPU, Alzeer was supervising a number of Master students and focused his research on the development of anticancer drug from Natural products. In 2014 founded Swiss scientific society for developing countries (SSSDC), as a neutral and non-profit organization devoted to promote communications, research, education and business between Switzerland and Developing countries. Alzeer is currently the director of SSSDC and the head of scientific board at Halal Certification Service, meanwhile Alzeer is a Senior Scientist at the University of Zurich, his research interest focused on rational use of natural product to design anti cancer drug and tackling different halal issues.